Komori
P

Pharmarise Holdings Corporation

2796RetailMicro cap
505JPY-0.4%
★ Watch (sign-up required)
Price history
¥505Latest-32.8%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

Pharmarise Holdings Corporation (Securities Code: 2796) is the holding company overseeing and managing the group. The group comprises 14 consolidated subsidiaries and operates primarily in four business areas: dispensing pharmacies, retail sales, medical record storage and management, and medical mall management. It seeks to expand revenue opportunities through synergies among these businesses. Its primary market is Japan, and its medium- to long-term strategy focuses on promoting the use of generic drugs, advancing community healthcare, addressing sustainability, and promoting digital transformation in healthcare (medical DX). Going forward, the group aims to promptly complete PMI, the post-acquisition and post-consolidation integration process, and improve profitability by expanding and streamlining its store network. Since becoming a holding company, the group has strengthened and integrated functions across the group and pursued a growth strategy that includes M&A. This report does not describe any subsequent events other than those specifically stated in the history of major business developments during the current fiscal year, the 40th fiscal year.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 20
PER
53.64How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
0.89How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
1.7%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥6.1bnShare price × number of shares. The value of the entire company.
Equity ratio
20.3%The proportion of assets funded by money that does not have to be repaid.
Operating margin
1.4%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
10.1%The average annual growth in sales over the past three years.
What to watch next
Early completion of post-integration PMI, with the degree of completion of business transfers and integration processes reflected in profitability
Approximately the next 12 months; disclosures indicate that completion is to be expeditedImpact HighLikelihood Medium
Progress toward the targets of the medium-term management plan Make a Leap 2027, including the achievability of sales, profit and ROIC targets
Fiscal 2026–2027Impact MediumLikelihood Medium
Expansion of medical DX operations, as the use of online medication counseling, online eligibility verification and electronic prescriptions increases
Second half of FY2026 to FY2027Impact MediumLikelihood Low
Reduction in the SG&A ratio, including confirmation of the effects of consolidating head-office functions and treasury management at headquarters
Fiscal 2026–2027Impact MediumLikelihood Medium
What to watch next
Loading
Who owns itTop holders total 67.7%
Listed holders 67.7%Everyone else 32.3%
㈱ビックフィールド26.20%
㈱スズケン20.10%
Ohno Sayoko (大野小夜子)4.50%
Ohno Rimichi (大野利美知)3.70%
ファーマライズ従業員持株会3.60%
中北薬品㈱3.40%
株式会社バイタルネット3.40%
平松仁1.00%
2 other listed holders1.80%
Who owns it
HolderOwnership (%)
㈱ビックフィールド26.20
㈱スズケン20.10
Ohno Sayoko (大野小夜子)4.50
Ohno Rimichi (大野利美知)3.70
ファーマライズ従業員持株会3.60
中北薬品㈱3.40
株式会社バイタルネット3.40
平松仁1.00
2 other listed holders1.80
This company's documents
Filings
Timely disclosures
Threads